Patients were randomised to the interleukin-1 beta monoclonal antibody, canakinumab, or placebo; canakinumab administered subcutaneously every 3 months over 3.7 years reduced cardiovascular death, myocardial infarction or stroke compared to placebo. The gene discussed is IL1B; the disease is myocardial infarction.